Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent

Drug Resistance Updates

Volumn 10, Issue 1-2, 2007, Pages 1-12

  Katsman, Alina ^a   Umezawa, Kazuo ^b   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Chemoresistance; Chemotherapy; DHMEQ; Immunoresistance; Immunotherapy; NF B; Nuclear localization signal; Resistance to apoptosis; YY1

Indexed keywords

BORTEZOMIB; CH 11; CISPLATIN; DEHYDROXYMETHYLEPOXYQUINOMICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; PACLITAXEL; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BLADDER CANCER; BONE DESTRUCTION; BREAST CANCER; CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL DEATH; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SENSITIZATION; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MONOTHERAPY; MULTIPLE MYELOMA; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; T CELL LEUKEMIA; THYROID CANCER; TUMOR IMMUNITY; URETER OBSTRUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL SURVIVAL; CYCLOHEXANONES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; NF-KAPPA B; TRANSLOCATION, GENETIC;

EID: 34247374766     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2007.01.002     Document Type: Article

References (79)

1. Ariga A., Namekawa J., Matsumoto N., Inoue J., and Umezawa K. Inhibition of TNFα-induced nuclear translocation and activation of NF-κB by dehydroxymethyl-epoxyquinomicin. J. Biol. Chem. 277 (2002) 24625-24630
2. Baeuerle P.A., and Henkel T. Function and activation of NF-kappaB in the immune system. Annu. Rev. Immunol. 12 (1994) 141-179
3. Baritaki, S., Huerta-Yepez, S., Sakai, T., Spandidos, D., Bonavida, B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: Upregulation of DR5 and inhibition of YY1. Mol. Cancer Ther. In press.
4. Bentires-Alj M., Dejardin E., Viatour P., et al. Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene 20 (2001) 2805-2813
5. Bernal-Mizrachi L., Lovly C.M., and Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 9220-9225
6. Biswas D.K., Shi Q., Baily S., Strickland I., Ghosh S., Pardee A.B., and Iglehart J.D. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10137-10142
7. Bonavida, B. Chemo- and immuno-sensitization of resistant tumor cells to cell death by apoptosis. Overcoming cancer drug resistance: two signal hit model in cell signaling for apoptosis by combination of sensitizing agents and chemotherapy. Ed. Bonavida, B. Transworld Research Network. In press.
8. Bonavida B., and Vega M.I. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma. Drug Resist. Updates 8 (2005) 27-41
9. Bubici C., Papa S., Pham C.G., Zazzeroni F., and Franzoso G. The NF-kappaB-mediated control of ROS and JNK signaling. Histol. Histopathol. 21 (2006) 69-80
10. Catley L., Tai Y.T., Chauhan D., and Anderson K.C. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist. Updates 8 (2005) 205-218
11. Chaicharoenpong C., Kato K., and Umezawa K. Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF-κB function. Bioorg. Med. Chem. 10 (2002) 3933-3939
12. Chen C., Edelstein L.C., and Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell Biol. 20 (2000) 2687-2695
13. Cretney E., Takeda K., and Smyth M.J. Cancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int. J. Biochem. Cell Biol. 39 (2007) 280-286
14. Cvetkovic R.S., and Perry C.M. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 66 (2006) 791-820
15. Dass S., Vital E.M., and Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother. 7 (2006) 2559-2570
16. del Peso L., Gonzalez-Garcia M., Page C., Herrera R., and Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278 (1997) 687-689
17. Demarchi F., and Brancolini C. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies. Drug Resist. Updates 8 (2005) 359-368
18. Dempsey P.W., Doyle S.E., He J.Q., and Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 14 (2003) 193-209
19. Deveraux Q.L., and Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 13 (1999) 239-252
20. Devin A., Cook A., Lin Y., Rodriguez Y., Kelliher M., and Liu Z. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 12 (2000) 419-429
21. Epinat J.C., and Gilmore T.D. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene 18 (1999) 6896-6909
22. Faivre S., Djelloul S., and Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol. 4 (2006) 407-420
23. Garban H.J., and Bonavida B. Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha-induced cytotoxicity. J. Biol. Chem. 276 (2001) 8918-8923
24. Ghobrial I.M., Witzig T.E., and Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55 (2005) 178-194
25. Ghosh S., May M.J., and Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16 (1998) 225-260
26. Gordon S., Akopyan G., Garban H., and Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25 (2006) 1125-1142
27. Hodi F.S., and Dranoff G. Combinatorial cancer immunotherapy. Adv. Immunol. 90 (2006) 341-368
28. Hongo F., Garban H., Huerta-Yepez S., Vega M., Jazirehi A.R., Mizutani Y., Miki T., and Bonavida B. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochem. Biophys. Res. Commun. 336 (2005) 692-701
29. Horie R., Watanabe M., Okamura T., Taira M., Shoda M., Motoji T., Utsunomiya A., Watanabe T., Higashihara M., and Umezawa K. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 20 (2006) 800-806
30. Horiguchi Y., Kuroda K., Nakashima J., Murai M., and Umezawa K. Antitumor effect of a novel nuclear factor-kappa b activation inhibitor in bladder cancer cells. Expert Rev. Anticancer Ther. 3 (2003) 793-798
31. XL expression. Oncogene 23 (2004) 4993-5003
32. Jarirehi A., and Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 24 (2005) 2121-2143
33. Jazirehi A., Huerta-Yepez S., Cheng G., and Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-kB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 65 (2005) 264-276
34. Jazirehi, A., Vega, M., Bonavida, B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy: circumvention of acquired resistance by specific pharmacological inhibitors (bortezomib, DHMEQ, PD098059). Cancer Res. In press.
35. Karin M. Nuclear factor-κB in cancer development and progression. Nature 441 (2006) 431-436
36. Kikuchi E., Horiguchi Y., Nakashima J., Kuroda K., Oya M., Ohigashi T., Takahashi N., Shima Y., Umezawa K., and Murai M. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res. 63 (2003) 107-110
37. Kreuz S., Siegmund D., Scheurich P., and Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell Biol. 21 (2001) 3964-3973
38. Kuroda K., Horiguchi Y., Nakashima J., Kikuchi E., Kanao K., Miyajima A., Ohigashi T., Umezawa K., and Murai M. Prevention of cancer cchexia by a novel nuclear factor KB inhibitor in prostate cancer. Clin. Cancer Res. 11 (2005) 5590-5594
39. Kuroki M., Huang J., Shibaguchi H., Tanaka T., Zhao J., Luo N., Hachimine K., Kinugasa T., Maekawa S., Enatsu S., Hamanaka W., Fukami T., and Kuroki M. Possible applications of antibodies or their genes in cancer therapy. Anticancer Res. 26 (2006) 4019-4025
40. LaCasse E.C., Baird S., Korneluk R.G., and MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 (1998) 3247-3259
41. Langstein H.N., and Norton J.A. Mechanisms of cancer cachexia. Hematol. Oncol. Clin. North Am. 5 (1991) 103-123
42. Lu T., and Stark G.R. Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle 3 (2004) 1114-1117
43. Luo J.L., Kamata H., and Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J. Clin. Invest. 115 (2005) 2625-2632
44. Matsumoto N., Ariga A., To-e S., Nakamura H., Agata N., Hirano S., Inoue J., and Umezawa K. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 10 (2000) 865-869
45. Matsumoto G., Namekawa J., Muta M., Nakamura T., Bando H., Tohyama K., Toi M., and Umezawa K. Targeting of Nuclear Factor KB pathways by dehydroxymethyl-epoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin. Cancer Res. 11 (2005) 1287-1293
46. Miyajima A., Kosaka T., Seta K., Asano T., Umezawa K., and Hayakawa M. Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. J. Urol. 169 (2003) 1159-1163
47. Nam N.H. Naturally occurring NF-kappaB inhibitors. Mini Rev. Med. Chem. 6 (2006) 945-951
48. Ng C.P., and Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv. Cancer Res. 85 (2002) 145-174
49. Norton J., Peacock J.L., and Morrison S.D. Cancer cachexia. Crit. Rev. Oncol. Hematol. 7 (1987) 289-327
50. Ohsugi T., Kumasaka T., Ishida A., Ishida T., Horie R., Watanabe T., Umezawa K., and Yamaguchi K. In vitro and in vivo antitumor activity of the NF-κB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. Leuk. Res. 30 (2006) 90-97
51. Oliver L., and Vallette F.M. The role of caspases in cell death and differentiation. Drug Resist. Updates 8 (2005) 163-170
52. Olivier S., Robe P., and Bours V. Can NF-kappaB be a target for novel and efficient anti-cancer agents?. Biochem. Pharmacol. 72 (2006) 1054-1068
53. Piva R., Belardo G., and Santoro M.G. NF-kappaB: a stress-regulated switch for cell survival. Antioxid. Redox Signal. 8 (2006) 478-486
54. Poma P., Notarbartolo M., Labbozzetta M., Sanguedolce R., Alaimo A., Carina V., Maurici A., Cusimano A., Cervello M., and D'Alessandro N. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int. J. Oncol. 28 (2006) 923-930
55. Ravi R., and Bedi A. NF-κB in cancer-a friend turned foe. Drug Resist. Updates 7 (2004) 53-67
56. Ravi R., Bedi G.C., Engstrom L.W., et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell Biol. 3 (2001) 409-416
57. Ravi R., Mookerjee B., van Hensbergen Y., et al. p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res. 58 (1998) 4531-4536
58. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat. Rev. Immunol. 2 (2002) 664-674
59. Ruan H.Y., Masuda M., Ito A., Umezawa K., Nakashima T., Yasumatsu R., Kuratomi Y., Yamamoto T., Weinstein I.B., and Komune S. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. Head Neck 28 (2006) 158-165
60. Salvi M., Vannucchi G., Campi I., Curro N., Dazzi D., Simonetta S., Bonara P., Rossi S., Sina C., Guastella C., Ratiglia R., and Beck-Peccoz P. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol. 156 (2007) 33-40
61. Sato A., Oya M., Ito K., Mizuno R., Horiguchi Y., Umezawa K., Hayakawa M., and Murai M. Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. Int. J. Oncol. 28 (2006) 841-846
62. Shukla S., Maclennan G.T., Marengo S.R., Resnick M.I., and Gupta S. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 64 (2005) 224-239
63. Starenki D., Namba H., Saenko V., Ohtsuru A., Umezawa K., and Yamashita S. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kB inhibitor, dehydroxymethyl-epoxyquinomicin. Clin. Cancer Res. 10 (2004) 6821-6829
64. Strassmann G., Fong M., Kenney J.S., and Jacob C.O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89 (1992) 1681-1684
65. Suh J., and Rabson A.B. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?. J. Cell. Biochem. 91 (2004) 100-117
66. Takatsuna H., Asagiri M., Kubota T., Oka K., Osada T., Sugiyama C., Saito H., Aoki K., Ohya K., Takayanagi H., and Umezawa K. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J. Bone Miner. Res. 20 (2005) 653-662
67. Tamm I. Antisense therapy in malignant diseases: status quo and quo vadis?. Clin. Sci. (London) 110 (2006) 427-442
68. Tang G., Minemoto Y., Dibling B., et al. Inhibition of JNK activation through NF-kappaB target genes. Nature 414 (2001) 313-317
69. Tatetsu H., Okuno Y., Nakamura M., Matsuno F., Sonoki T., Taniguchi I., Uneda S., Umezawa K., Mitsuya H., and Hata H. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-KB inhibitor, induces apoptosis in multiple myeloma cells in an IKBA-independent manner. Mol. Cancer Ther. 4 (2005) 1114-1120
70. Umezawa K. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci. 97 (2006) 990-995
71. Vega M., Jazirehi A., and Bonavida B. New targets identified for therapeutic intervention in the reversal of rituximab and drug resistant AIDS-B-NHL. Proc. Amer. Assoc. Cancer Res. 47 (2005) 1274 abstract # 1274
72. Vega M., Jazirehi A., and Bonavida B. Reversal of rituximab-resistant AIDS-B-NHL clone to chemotherapeutic drug-induced apoptosis by Bortezomib and DHMEQ. Blood 106 (2005) 436a
73. Vega M., Jazirehi A., Huerta-Yepez S., and Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-XL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-κB activity: role of YY1 and Bcl-XL in Fas resistance and chemoresistance, respectively. J. Immunol. 175 (2005) 2174-2183
74. Vermeulen L., Vanden Berghe W., and Haegeman G. Regulation of NF-kappaB transcriptional activity. Cancer Treat. Res. 130 (2006) 89-102
75. Wakamatsu K., Nanki T., Miyasaka N., Umezawa K., and Kubota T. Effect of a small molecule inhibitor of nuclear factor-κB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res. Ther. 7 (2005) 1348-1359
76. Wang C.C., Chen J.J., and Yang P.C. Multifunctional transcription factor YY1: a therapeutic target in human cancer?. Expert Opin. Ther. Targets 10 (2006) 253-266
77. Watanabe M., Dewan M.Z., Okamura T., Sasaki M., Itoh K., Higashihara M., Mizoguchi H., Honda M., Sata T., Watanabe T., Yamamoto N., Umezawa K., and Horie R. A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int. J. Cancer 114 (2005) 32-38
78. Watanabe M., Ohsugi T., Shoda M., Ishida T., Aizawa S., Maruyama-Nagai M., Utsunomiya A., Koga S., Yamada Y., Kamihira S., Okayama A., Kikuchi H., Uozumi K., Yamaguchi K., Higashihara M., Umezawa K., Watanabe T., and Horie R. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 106 (2005) 2462-2471
79. Younes A., Garg A., and Aggarwal B.B. Nuclear transcription factor-kappaB in Hodgkin's disease. Leuk. Lymphoma 44 (2003) 929-935